Invention Grant
- Patent Title: Insulin glargine/lixisenatide fixed ratio formulation
-
Application No.: US14965586Application Date: 2015-12-10
-
Publication No.: US09950039B2Publication Date: 2018-04-24
- Inventor: Elisabeth Souhami , Louise Silvestre
- Applicant: Sanofi-Aventis Deutschland GmbH
- Applicant Address: DE Frankfurt am Main
- Assignee: SANOFI-AVENTIS DEUTSCHLAND GMBH
- Current Assignee: SANOFI-AVENTIS DEUTSCHLAND GMBH
- Current Assignee Address: DE Frankfurt am Main
- Agency: McDonnell Boehnen Hulbert & Berghoff LLP
- Priority: EP14197685 20141212; EP15193940 20151110
- Main IPC: A61K38/26
- IPC: A61K38/26 ; A61K38/28 ; A61P3/10
Abstract:
The present invention refers to a pharmaceutical composition comprising (a) lixisenatide or/and a pharmaceutically acceptable salt thereof, and (b) insulin glargine or/and a pharmaceutically acceptable salt thereof, wherein the compound (b) and compound (a) are present in a fixed ratio.
Public/Granted literature
- US20160199452A1 Insulin glargine/lixisenatide fixed ratio formulation Public/Granted day:2016-07-14
Information query
IPC分类:
